Yes I saw that as well, a very good post as always from akamali. Without a doubt, you cannot overstate the importance of a single dose antibiotic that is comparable to dapto, it would capture a large chunk of the market very rapidly. Patient compliance is a big issue and I think most docs would jump at the chance to administer an agent in a single dose, ensuring 100% dosing compliance, with only a follow up a few weeks later. The market doesn't yet value Brilacidin in the CTIX pipeline, but that wont last for much longer.
Great article today talking about the huge opportunity for B, dark horse is a good way of viewing this drug given how under the radar it still is. Few more months and the skeptics and the market alike will have no choice but to recognize the proper value of this drug once the positive results are released, and a big pharma steps up to partner for phase 3 and puts a solid 40-50 million in the CTIX bank account instantly.
News 
Market Data 
Discover 
